Universal Beteiligungs und Servicegesellschaft mbH Makes New Investment in Vaxcyte, Inc. (NASDAQ:PCVX)

Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 103,683 shares of the company's stock, valued at approximately $8,487,000. Universal Beteiligungs und Servicegesellschaft mbH owned 0.08% of Vaxcyte at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. increased its stake in Vaxcyte by 4.6% during the fourth quarter. Vanguard Group Inc. now owns 11,961,687 shares of the company's stock worth $979,184,000 after acquiring an additional 521,204 shares during the last quarter. Capital Research Global Investors lifted its stake in shares of Vaxcyte by 26.8% in the 4th quarter. Capital Research Global Investors now owns 6,210,523 shares of the company's stock worth $508,393,000 after acquiring an additional 1,312,302 shares during the period. Franklin Resources Inc. lifted its stake in Vaxcyte by 3.0% during the fourth quarter. Franklin Resources Inc. now owns 2,869,332 shares of the company's stock valued at $234,884,000 after purchasing an additional 82,997 shares during the last quarter. Geode Capital Management LLC boosted its stake in Vaxcyte by 3.8% in the 4th quarter. Geode Capital Management LLC now owns 2,802,888 shares of the company's stock worth $229,495,000 after purchasing an additional 102,106 shares during the period. Finally, Alliancebernstein L.P. grew its position in Vaxcyte by 8.1% during the fourth quarter. Alliancebernstein L.P. now owns 1,779,362 shares of the company's stock valued at $145,659,000 after purchasing an additional 133,448 shares in the last quarter. 96.78% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the stock. The Goldman Sachs Group reduced their target price on shares of Vaxcyte from $138.00 to $100.00 and set a "buy" rating for the company in a research note on Tuesday, April 1st. Needham & Company LLC reissued a "buy" rating and issued a $90.00 target price on shares of Vaxcyte in a research note on Tuesday, April 8th. Guggenheim reaffirmed a "buy" rating and set a $160.00 price objective on shares of Vaxcyte in a research report on Wednesday, March 12th. Cantor Fitzgerald started coverage on Vaxcyte in a report on Tuesday, April 22nd. They issued an "overweight" rating for the company. Finally, Evercore ISI upgraded shares of Vaxcyte to a "strong-buy" rating in a research note on Monday, March 31st. Nine analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, Vaxcyte has an average rating of "Buy" and an average price target of $136.50.

Vaxcyte Trading Down 2.3%

Vaxcyte stock traded down $0.81 during trading hours on Wednesday, hitting $33.84. 1,201,943 shares of the stock traded hands, compared to its average volume of 1,419,296. Vaxcyte, Inc. has a one year low of $27.66 and a one year high of $121.06. The company has a market cap of $4.37 billion, a PE ratio of -7.36 and a beta of 1.20. The firm's 50-day moving average price is $32.22 and its two-hundred day moving average price is $65.79.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last issued its earnings results on Wednesday, May 14th. The company reported ($1.04) earnings per share for the quarter, missing analysts' consensus estimates of ($1.02) by ($0.02). During the same period last year, the firm earned ($0.85) earnings per share. On average, sell-side analysts expect that Vaxcyte, Inc. will post -4.21 earnings per share for the current fiscal year.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.